Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Tscan Therapeutics Inc’s stock clocked out at $0.96, down -2.27% from its previous closing price of $0.99. In other words, the price has decreased by -$2.27 from its previous closing price. On the day, 0.64 million shares were traded. TCRX stock price reached its highest trading level at $0.9985 during the session, while it also had its lowest trading level at $0.91.
Ratios:
To gain a deeper understanding of TCRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.44 and its Current Ratio is at 6.44. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.62.
On May 16, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $12.
On May 13, 2024, Needham started tracking the stock assigning a Buy rating and target price of $11.Needham initiated its Buy rating on May 13, 2024, with a $11 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when Lynx1 Capital Management LP bought 1,388,794 shares for $1.20 per share. The transaction valued at 1,666,553 led to the insider holds 6,746,141 shares of the business.
Lynx1 Capital Management LP bought 1,200,000 shares of TCRX for $1,440,000 on May 20 ’25. The 10% Owner now owns 7,946,141 shares after completing the transaction at $1.20 per share. On Dec 13 ’24, another insider, Lynx1 Capital Management LP, who serves as the 10% Owner of the company, bought 100,000 shares for $2.90 each. As a result, the insider paid 290,140 and bolstered with 5,357,347 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCRX now has a Market Capitalization of 54636968 and an Enterprise Value of -34194032. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.49 while its Price-to-Book (P/B) ratio in mrq is 0.38. Its current Enterprise Value per Revenue stands at -4.06 whereas that against EBITDA is 0.235.
Stock Price History:
The Beta on a monthly basis for TCRX is 1.21, which has changed by -0.7869469 over the last 52 weeks, in comparison to a change of 0.1028198 over the same period for the S&P500. Over the past 52 weeks, TCRX has reached a high of $4.94, while it has fallen to a 52-week low of $0.96. The 50-Day Moving Average of the stock is -45.07%, while the 200-Day Moving Average is calculated to be -42.75%.
Shares Statistics:
It appears that TCRX traded 649.02K shares on average per day over the past three months and 921750 shares per day over the past ten days. A total of 52.47M shares are outstanding, with a floating share count of 46.42M. Insiders hold about 18.20% of the company’s shares, while institutions hold 58.03% stake in the company. Shares short for TCRX as of 1761868800 were 1742176 with a Short Ratio of 2.68, compared to 1759190400 on 1567792. Therefore, it implies a Short% of Shares Outstanding of 1742176 and a Short% of Float of 3.73.
Earnings Estimates
A comprehensive evaluation of Tscan Therapeutics Inc (TCRX) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.19 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$1.01 and -$1.97 for the fiscal current year, implying an average EPS of -$1.24. EPS for the following year is -$1.0, with 4.0 analysts recommending between -$0.77 and -$1.48.
Revenue Estimates
In. The current quarter, 5 analysts expect revenue to total $2.04M. It ranges from a high estimate of $2.5M to a low estimate of $500k. As of. The current estimate, Tscan Therapeutics Inc’s year-ago sales were $665kFor the next quarter, 5 analysts are estimating revenue of $2.5M. There is a high estimate of $2.5M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 6 analysts have provided revenue estimates for TCRX’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $8.3M, resulting in an average revenue estimate of $10.68M. In the same quarter a year ago, actual revenue was $2.82M
